Canine status epilepticus: A translational platform for human therapeutic trials

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy. Many potent compounds have been discovered in animal models of SE. But they may never be useful for chronic treatment of epilepsy and thus not available for human use. Naturally occurring canine SE may become a translational platform for evaluating these compounds for eventual use in human trials. A pilot study of levetiracetam in canine SE demonstrated a 56% response rate compared to 10% for placebo. Based on these results we have obtained an NIH R-21 to further evaluate canine SE as a translational platform for developing new approaches for treating human SE.

Original languageEnglish (US)
Pages (from-to)31-34
Number of pages4
Issue numberSUPPL. 8
StatePublished - Oct 2011


  • Canine epilepsy
  • Status epilepticus
  • Translational platform


Dive into the research topics of 'Canine status epilepticus: A translational platform for human therapeutic trials'. Together they form a unique fingerprint.

Cite this